Financhill
Back

Halozyme Therapeutics, Inc. 10K Form

Sell
36

HALO
Halozyme Therapeutics, Inc.

Last Price:
$63.57
Seasonality Move:
2.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive HALO News And Ratings

See the #1 stock for the next 7 days that we like better than HALO

HALO Financial Statistics

Sales & Book Value

Annual Sales: $1.4B
Cash Flow: $217.6M
Price / Cash Flow: 12.65
Annual Sales: $0.41
Price / Book: 160.73

Profitability

EPS (TTM): 2.49180
Net Income (TTM): $316.9M
Gross Margin: $1.1B
Return on Equity: 91.5%
Return on Assets: 13.96%

Halozyme Therapeutics, Inc. Earnings Forecast

Key Halozyme Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 25 years for HALO is 78.13%.
  • The Selling, General & Administrative Expenses for HALO have been equal to 14.83% of Gross Profit Margin.
  • The Research & Development expenses have been 5.83% of Revenue.
  • The Interest Expense is 5.72% of Operating Income.
  • The Net Earning history of HALO is 22.69% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

Halozyme Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: HALO
CUSIP: 40637H
Website: halozyme.com

Debt

Debt-to-Equity Ratio: 44.6
Current Ratio: 4.66
Quick Ratio: 3.35

Price-to-Earnings

Trailing P/E Ratio: 25.99
Forward P/E Ratio: 6.75

HALO Technical Analysis vs Fundamental Analysis

Sell
36
Halozyme Therapeutics, Inc. (HALO) is a Sell

Is Halozyme Therapeutics, Inc. a Buy or a Sell?